3+3 Design [Design Issues]

posted by Pharma_88 – India, 2020-01-07 08:09 (470 d 04:06 ago) – Posting: # 21062
Views: 2,549

Hello All,

This is regarding 3+3 design for Phase-I trial. I have searched online and found some articles on design. My Question is that once the group/cohort is completed with 3 patients, whether same patients will be enrolled in next cohort or new patient will be enrolled? Further, in next cohort suppose 1 patient is withdarwn or have some AE then its compulsory to add 3 more patients to inline with multiplication of 3?


Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 10 (0 registered, 10 guests [including 2 identified bots]).
Forum time: Wednesday 13:16 CEST (Europe/Vienna)

In the Middles Ages the lingua franca of science was Latin.
Nowadays the language of science is bad English.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz